← Back to Screener
Myomo Inc. (MYO)
Price$0.90
Favorite Metrics
Price vs S&P 500 (26W)-25.84%
Price vs S&P 500 (4W)18.57%
Market Capitalization$34.65M
All Metrics
Book Value / Share (Quarterly)$0.30
P/TBV (Annual)3.56x
Revenue Growth (3Y)38.05%
Cash Flow / Share (Quarterly)$-0.46
Price vs S&P 500 (YTD)-5.07%
Gross Margin (TTM)65.70%
Net Profit Margin (TTM)-38.05%
EPS (TTM)$-0.37
10-Day Avg Trading Volume0.28M
EPS Excl Extra (TTM)$-0.37
Revenue Growth (5Y)40.10%
EPS (Annual)$-0.37
ROI (Annual)-68.83%
Gross Margin (Annual)65.70%
Net Profit Margin (5Y Avg)-48.63%
Cash / Share (Quarterly)$0.48
Revenue Growth QoQ (YoY)-5.93%
ROA (Last FY)-40.31%
Revenue Growth TTM (YoY)25.73%
EBITD / Share (TTM)$-0.32
ROE (5Y Avg)-97.63%
Operating Margin (TTM)-35.19%
Cash Flow / Share (Annual)$-0.46
P/B Ratio3.04x
P/B Ratio (Quarterly)3.07x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)0.78x
Net Interest Coverage (TTM)-21.58x
ROA (TTM)-40.92%
EPS Incl Extra (Annual)$-0.37
Current Ratio (Annual)3.30x
Quick Ratio (Quarterly)2.69x
3-Month Avg Trading Volume0.49M
52-Week Price Return-79.41%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.26
P/S Ratio (Annual)0.85x
Asset Turnover (Annual)1.06x
52-Week High$4.99
Operating Margin (5Y Avg)-47.95%
EPS Excl Extra (Annual)$-0.37
CapEx CAGR (5Y)135.77%
Tangible BV CAGR (5Y)-12.57%
26-Week Price Return-18.95%
Quick Ratio (Annual)2.69x
13-Week Price Return-5.22%
Total Debt / Equity (Annual)0.98x
Current Ratio (Quarterly)3.30x
Enterprise Value$31.735
Revenue / Share Growth (5Y)-15.56%
Asset Turnover (TTM)1.08x
Book Value / Share Growth (5Y)-34.81%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)4.46x
Pretax Margin (Annual)-36.82%
Cash / Share (Annual)$0.48
3-Month Return Std Dev74.03%
Gross Margin (5Y Avg)69.15%
Net Income / Employee (TTM)$-0
ROE (Last FY)-136.57%
Net Interest Coverage (Annual)-6.51x
EPS Basic Excl Extra (Annual)$-0.37
Receivables Turnover (TTM)10.33x
Total Debt / Equity (Quarterly)0.98x
EPS Incl Extra (TTM)$-0.37
Receivables Turnover (Annual)10.33x
ROI (TTM)-73.68%
P/S Ratio (TTM)0.85x
Pretax Margin (5Y Avg)-47.78%
Revenue / Share (Annual)$0.98
Tangible BV / Share (Annual)$0.26
Price vs S&P 500 (52W)-114.05%
Year-to-Date Return-1.14%
5-Day Price Return13.59%
EPS Normalized (Annual)$-0.37
ROA (5Y Avg)-53.59%
Net Profit Margin (Annual)-38.05%
Month-to-Date Return33.16%
Cash Flow / Share (TTM)$-0.32
EBITD / Share (Annual)$-0.32
Operating Margin (Annual)-35.19%
LT Debt / Equity (Annual)0.98x
ROI (5Y Avg)-84.08%
LT Debt / Equity (Quarterly)0.98x
EPS Basic Excl Extra (TTM)$-0.37
P/TBV (Quarterly)3.56x
P/B Ratio (Annual)3.07x
Inventory Turnover (TTM)4.46x
Pretax Margin (TTM)-36.82%
Book Value / Share (Annual)$0.30
Price vs S&P 500 (13W)-7.60%
Beta1.45x
Revenue / Share (TTM)$0.97
ROE (TTM)-95.35%
52-Week Low$0.60
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Orthopedic & Prosthetic Devices(25)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
MYOMyomo Inc. | 0.85x | 40.10% | 65.70% | -35.19% | $0.90 |
ISRGIntuitive Surgical Inc. | 16.54x | 18.22% | 66.00% | 29.27% | $465.60 |
EWEdwards Lifesciences Corp | 7.77x | 6.70% | 78.01% | 18.41% | $81.44 |
STESTERIS plc | 3.81x | 12.49% | 44.11% | 17.03% | $226.41 |
ZBHZimmer Biomet Holdings, Inc. | 2.31x | 3.22% | 69.71% | 13.34% | $95.48 |
ALGNAlign Technology Inc | 3.41x | 10.30% | 68.27% | 13.53% | $191.66 |
SNNSmith & Nephew plc | 2.37x | 6.21% | 68.01% | 12.88% | $34.21 |
MSAMine Safety Incorporated | 3.60x | 6.82% | 46.46% | 19.83% | $173.50 |
ESTAEstablishment Labs Holdings Inc. | 9.30x | 20.04% | 69.32% | -18.48% | $66.93 |
ENOVEnovis Corporation | 0.68x | -6.05% | 58.16% | -50.09% | $26.27 |
CDRECadre Holdings, Inc. | 2.19x | 8.57% | 42.54% | 11.04% | $30.51 |
About
Myomo Inc manufactures MyoPro, an FDA-cleared Class II myoelectric orthosis designed to restore upper limb function in patients with neuromuscular disorders. The company distributes through orthotics and prosthetics providers worldwide and the Veterans Health Administration, while generating revenue through direct insurance billing for patient usage.